Every lot is third-party tested — certificates published against the lot number.
PEPSResearch Supply
Cart
≥99% (HPLC)Ships from United States

Ipamorelin

Selective growth hormone secretagogue

Ipamorelin — 5 mg vial

A pentapeptide ghrelin-receptor agonist, characterised as the first selective GH secretagogue — releasing GH without the ACTH and cortisol rise of earlier GHRPs.

Ipamorelin acts at the GHS-R1a (ghrelin) receptor rather than the GHRH receptor. Its defining property in the originating literature is selectivity: in swine it did not raise ACTH or cortisol even at doses far above the GH ED50.

It reached phase 2 human trials for postoperative ileus before development was discontinued. Supplied lyophilised. Not an approved medicine.

Specification

CAS number170851-70-4
Molecular formulaC38H49N9O5
Molecular weight711.86 g/mol
Purity≥99% (HPLC)
SequenceAib-His-D-2-Nal-D-Phe-Lys-NH2
AppearanceLyophilised white powder
StorageStore at -20°C, protect from light

Batch records & certificates

Every lot we hold of this compound, across all warehouses. The certificate is tied to that lot number — not a generic sample document.

LotWarehousePurityTestedLaboratoryDocuments
IP25-0316India99%11 Jul 2026Colmaric AnalyticalsCOA pending
IP25-0301United States99.2%30 May 2026Janoshik AnalyticalCOA pending

Published research

Full research profile

In human clinical trials

Animal model

Ipamorelin, the first selective growth hormone secretagogue

Raun K, et al. · European Journal of Endocrinology · 1998

The originating characterisation paper, establishing GHS-R1a activity and the absence of ACTH/cortisol release in swine.

PMID 9849822DOI 10.1530/eje.0.1390552
Animal model

Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats

Johansen PB, et al. · Growth Hormone & IGF Research · 1999

Chronic administration produced dose-dependent longitudinal bone growth and body weight gain in rats.

PMID 10373343DOI 10.1054/ghir.1999.9998
Human clinical

Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers

Gobburu JV, et al. · Pharmaceutical Research · 1999

A randomised human volunteer study characterising the PK/PD relationship of GH release following administration.

PMID 10496658DOI 10.1023/a:1018955126402
All products listed on this site are sold strictly as laboratory reagents for in-vitro research and analytical use. They are not drugs, foods, cosmetics or medical devices, and are not intended to diagnose, treat, cure or prevent any disease. They are not for human or veterinary consumption or administration. Purchasers must be qualified researchers or institutions and are solely responsible for compliance with all applicable laws.